An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation.
about
Glycosylation of glycolipids in cancer: basis for development of novel therapeutic approachesTumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancerPhase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.Ganglioside GD2 in reception and transduction of cell death signal in tumor cells.The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma.Anti-proliferative and pro-apoptotic activity of GD2 ganglioside-specific monoclonal antibody 3F8 in human melanoma cells.Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells.Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapy.Disialyl gangliosides enhance tumor phenotypes with differential modalities.Targeting of tumor-associated gangliosides with antibodies affects signaling pathways and leads to cell death including apoptosis.Antiproliferative and Apoptotic Activity of Chamaecyparis obtusa Leaf Extract against the HCT116 Human Colorectal Cancer Cell Line and Investigation of the Bioactive Compound by Gas Chromatography-Mass Spectrometry-Based Metabolomics.Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis.Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias.
P2860
Q21129299-BE09469C-7B9B-41F1-A790-9D08610716A1Q28396304-7952E28A-F1FC-4630-A559-7C3C89A0DABDQ33597441-B0D133CC-BD62-4699-9039-6D6382AF16D4Q33613772-FF75E9D7-DDF9-4FFD-A2D0-D7A1FFBCCEBFQ34186886-BDBB01F3-489C-4DD3-86A4-80D812CA8FFCQ36060249-3C21BA2F-2A04-42E6-9927-0CAF7F2FA09DQ36597374-B285C0A1-7807-4329-AC9C-A99B4AEE6237Q37592957-16AD6546-F0EA-4F84-9320-3231C1B6580FQ37974938-06781507-537B-4320-AD70-732EC4C01D1EQ38024047-3EB1ABEF-045A-4FD8-939F-A900E8A64A8BQ38352205-0B5A231E-A907-4740-AA6A-730F3991198DQ38829712-CF6B9E63-BDE4-4DDD-94F0-FC4FE002F0B0Q40415805-4906F0E8-1F7E-4BBD-ABD6-8386F25EA072Q46963821-06C69CCE-CA60-46AC-A93E-1FC101391BDD
P2860
An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
An anti-GD2 monoclonal antibod ...... n terminal kinase) activation.
@en
An anti-GD2 monoclonal antibod ...... cell lung cancer cells via JNK
@nl
type
label
An anti-GD2 monoclonal antibod ...... n terminal kinase) activation.
@en
An anti-GD2 monoclonal antibod ...... cell lung cancer cells via JNK
@nl
prefLabel
An anti-GD2 monoclonal antibod ...... n terminal kinase) activation.
@en
An anti-GD2 monoclonal antibod ...... cell lung cancer cells via JNK
@nl
P2093
P2860
P1476
An anti-GD2 monoclonal antibod ...... n terminal kinase) activation.
@en
P2093
Haruhiko Kawaguchi
Koichi Furukawa
Ryuzo Ueda
Shigeki Sato
Shoko Yoshida
P2860
P304
P356
10.1111/J.1349-7006.2002.TB01324.X
P577
2002-07-01T00:00:00Z